CN113993898B - 结合ret的人抗体及其使用方法 - Google Patents

结合ret的人抗体及其使用方法 Download PDF

Info

Publication number
CN113993898B
CN113993898B CN202080042521.7A CN202080042521A CN113993898B CN 113993898 B CN113993898 B CN 113993898B CN 202080042521 A CN202080042521 A CN 202080042521A CN 113993898 B CN113993898 B CN 113993898B
Authority
CN
China
Prior art keywords
ser
antibody
ret
gly
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080042521.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN113993898A (zh
Inventor
C·戴利
G·瑟斯顿
N·帕帕佐普洛斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of CN113993898A publication Critical patent/CN113993898A/zh
Application granted granted Critical
Publication of CN113993898B publication Critical patent/CN113993898B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202080042521.7A 2019-04-10 2020-04-09 结合ret的人抗体及其使用方法 Active CN113993898B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962832218P 2019-04-10 2019-04-10
US62/832,218 2019-04-10
PCT/US2020/027554 WO2020210551A1 (en) 2019-04-10 2020-04-09 Human antibodies that bind ret and methods of use thereof

Publications (2)

Publication Number Publication Date
CN113993898A CN113993898A (zh) 2022-01-28
CN113993898B true CN113993898B (zh) 2025-05-27

Family

ID=70554175

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080042521.7A Active CN113993898B (zh) 2019-04-10 2020-04-09 结合ret的人抗体及其使用方法

Country Status (11)

Country Link
US (1) US20220185900A1 (cg-RX-API-DMAC7.html)
EP (1) EP3953390A1 (cg-RX-API-DMAC7.html)
JP (3) JP7511576B2 (cg-RX-API-DMAC7.html)
KR (2) KR102967743B1 (cg-RX-API-DMAC7.html)
CN (1) CN113993898B (cg-RX-API-DMAC7.html)
AU (1) AU2020270966B2 (cg-RX-API-DMAC7.html)
CA (1) CA3134258A1 (cg-RX-API-DMAC7.html)
IL (1) IL287067A (cg-RX-API-DMAC7.html)
MA (1) MA55615A (cg-RX-API-DMAC7.html)
MX (1) MX2021012335A (cg-RX-API-DMAC7.html)
WO (1) WO2020210551A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4277904A1 (en) 2021-01-15 2023-11-22 Seagen Inc. Immunomodulatory antibody-drug conjugates
MX2023009113A (es) 2021-02-03 2023-08-10 Seagen Inc Conjugados y compuestos inmunoestimulantes.
WO2023144790A1 (en) * 2022-01-31 2023-08-03 Glaxosmithkline Intellectual Property (No.3) Limited Prevention and treatment of headaches
EP4518905A1 (en) 2022-05-06 2025-03-12 Seagen Inc. Immunomodulatory antibody-drug conjugates
IL318450A (en) 2022-08-03 2025-03-01 Seagen Inc Immunostimulatory ANTI-PD-L1-Drug conjugates
EP4321522A1 (en) 2022-08-12 2024-02-14 Seagen Inc. Cytotoxic compounds and conjugates thereof
AU2024403267A1 (en) * 2023-12-20 2026-07-16 Dianthus Therapeutics Opco, Inc. Pharmaceutical compositions comprising antibodies for treatment of c1s mediated disorders and methods of using the same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1941909A1 (en) * 2005-10-24 2008-07-09 Takeda Pharmaceutical Company Limited Preventives/remedies for cancer
CN104768974A (zh) * 2012-08-22 2015-07-08 瑞泽恩制药公司 GFRα3的人抗体及其使用方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6677135B1 (en) 1996-05-08 2004-01-13 Biogen, Inc. Ret ligand (RetL) for stimulating neutral and renal growth
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
JP2008546716A (ja) * 2005-06-17 2008-12-25 バイオジェン・アイデック・エムエイ・インコーポレイテッド 抗GFRα3抗体
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
ES2701649T3 (es) 2009-01-14 2019-02-25 Ablynx Nv Administración pulmonar de dominios variables individuales de inmunoglobulina y constructos de los mismos
CN102459332B (zh) 2009-06-05 2015-08-19 埃博灵克斯股份有限公司 用于预防和/或治疗呼吸道感染的单价、二价和三价抗人呼吸道合胞病毒(hrsv)纳米抗体构建体
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
KR102288722B1 (ko) * 2013-08-30 2021-08-12 모멘티브 퍼포먼스 머티리얼즈 인크. 아미노산을 갖는 수분 경화성 화합물
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
AU2016332900C1 (en) 2015-09-29 2024-07-04 Amgen Inc. ASGR inhibitors
KR101859576B1 (ko) * 2016-06-30 2018-05-18 가톨릭대학교 산학협력단 Kif5b-ret 융합 단백질을 특이적으로 검출하는 항체 및 이의 용도
KR20200059243A (ko) 2017-09-20 2020-05-28 리제너론 파마슈티칼스 인코포레이티드 패신저 유전자 돌연변이 부담이 높은 종양을 가진 환자에 대한 면역 치료요법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1941909A1 (en) * 2005-10-24 2008-07-09 Takeda Pharmaceutical Company Limited Preventives/remedies for cancer
CN104768974A (zh) * 2012-08-22 2015-07-08 瑞泽恩制药公司 GFRα3的人抗体及其使用方法

Also Published As

Publication number Publication date
KR20260079447A (ko) 2026-06-01
MX2021012335A (es) 2021-11-12
MA55615A (fr) 2022-02-16
JP7688175B2 (ja) 2025-06-03
KR20210150509A (ko) 2021-12-10
JP7904951B2 (ja) 2026-08-13
CN113993898A (zh) 2022-01-28
WO2020210551A1 (en) 2020-10-15
KR102967743B1 (ko) 2026-05-26
JP7511576B2 (ja) 2024-07-05
JP2024024114A (ja) 2024-02-21
IL287067A (en) 2021-12-01
EP3953390A1 (en) 2022-02-16
AU2020270966A1 (en) 2021-10-28
AU2020270966B2 (en) 2025-05-15
JP2025113406A (ja) 2025-08-01
US20220185900A1 (en) 2022-06-16
JP2022527373A (ja) 2022-06-01
CA3134258A1 (en) 2020-10-15

Similar Documents

Publication Publication Date Title
US10947312B2 (en) Human antibodies to GFRα3 and methods of making thereof
KR101859911B1 (ko) 사람 gdf8에 대한 항체
KR102163136B1 (ko) 항-cd3 항체, cd3 및 cd20에 결합하는 이특이적 항원-결합 분자, 및 이들의 사용
JP7688175B2 (ja) Retを結合するヒト抗体およびその使用方法
KR20150103682A (ko) 항-pdgfr-베타 항체 및 이의 용도
RU2821548C2 (ru) Человеческие антитела, связывающие ret, и способы их применения
HK1261378B (en) Human antibodies to gfralpha3 and methods of use thereof
HK1261378A1 (en) Human antibodies to gfr 3 and methods of use thereof
HK1206037B (en) Human antibodies to gfr 3 and methods of use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant